J Drugs Dermatol. 2021 Dec 1;20(12):ss4-s14. doi: 10.36849/jdd.M1221.
Preventive measures, earlier diagnosis, and markedly improved anticancer treatments have resulted in increasingly more patients living with or surviving cancer. Frequently cancer treatment-related cutaneous adverse events (cAEs) occur, which can severely impact patients' quality of life (QoL) and interfere with anticancer treatment outcomes. Currently, cAEs related to anticancer treatment may be under-appreciated to prevent or provide early and effective treatment. The Nordic European Cutaneous Oncodermatology Management (NECOM) project explored clinical insights in cAEs and focused on skincare regimens involving hygiene, moisturization, sun protection, and camouflage products. The NECOM panel discussed and reached a consensus on evidence and opinion-based best practice recommendations for oncology skincare programs to support all stakeholders in the Nordic European healthcare setting working with oncology patients throughout the entire continuum of care achieve optimal outcomes, improving patients' QoL. J Drugs Dermatol. 2021;20:12(Suppl):s4-14.
预防措施、早期诊断和显著改善的抗癌治疗使得越来越多的患者能够生存或幸存于癌症。经常会发生与癌症治疗相关的皮肤不良反应（cAEs），这可能严重影响患者的生活质量（QoL）并干扰抗癌治疗结果。目前，可能对预防或提供早期和有效治疗相关的 cAEs 认识不足。北欧欧洲皮肤肿瘤医学管理（NECOM）项目探讨了 cAEs 的临床见解，并侧重于涉及卫生、保湿、防晒和伪装产品的护肤方案。NECOM 小组讨论并就基于证据和意见的最佳实践建议达成共识，以支持北欧欧洲医疗保健环境中的所有利益相关者，与整个护理连续体中的肿瘤患者一起工作，实现最佳结果，提高患者的生活质量。J 皮肤病药物杂志。2021;20:12（增刊）：s4-14。
